JZT(000989)2023-10-25 16:00Financial Performance - The company's operating revenue for the current reporting period is ¥551,322,356.98, a decrease of 3.99% compared to the same period last year[13]. - Net profit attributable to shareholders for the current reporting period is ¥43,908,213.25, an increase of 91.92% year-on-year[13]. - Net profit attributable to shareholders after deducting non-recurring gains and losses is ¥34,247,726.32, up 97.93% compared to the same period last year[13]. - The net profit for the third quarter is 287,515,147.59 yuan, a decrease from 388,794,815.90 yuan in the same period last year, representing a decline of approximately 26%[29]. - The total profit for the quarter is 346,940,382.42 yuan, down from 503,003,968.20 yuan year-on-year, indicating a decrease of about 31%[29]. - The company’s operating profit for the quarter is 346,347,507.16 yuan, down from 500,149,564.49 yuan year-on-year, reflecting a decrease of approximately 31%[29]. - The total comprehensive income attributable to the parent company for the current period is CNY 302,296,687.66, compared to CNY 373,677,043.63 in the previous period, reflecting a decrease of approximately 19.1%[32]. - Basic and diluted earnings per share for the current period are both CNY 0.3373, down from CNY 0.4572 in the previous period, indicating a decline of about 26.2%[32]. Assets and Liabilities - Total assets increased to ¥5,398,434,079.72 from ¥5,239,728,801.58, representing a growth of approximately 3.03%[1]. - Current liabilities rose to ¥1,366,623,705.14 from ¥1,159,506,104.85, an increase of about 17.88%[1]. - Non-current liabilities decreased to ¥91,070,406.22 from ¥98,955,228.70, a decline of approximately 8.93%[1]. - Total liabilities increased to ¥1,457,694,111.36 from ¥1,258,461,333.55, a rise of about 15.83%[1]. - Total equity attributable to shareholders decreased to ¥3,945,310,836.44 from ¥3,984,827,136.94, a reduction of about 1.00%[5]. - The total current assets increased to ¥2,972,101,611.61 from ¥2,797,935,355.28, reflecting a growth of about 6.19%[6]. Cash Flow - The net cash flow from operating activities decreased by 87.94% year-on-year, amounting to ¥45,668,461.80[13]. - The net cash flow from operating activities for the current period is CNY 45,668,461.80, compared to CNY 378,827,633.83 in the previous period, indicating a significant decline[33]. - The net cash flow from investing activities for the current period is -CNY 612,418,606.77, slightly worse than -CNY 598,740,917.76 in the previous period[35]. - The net cash flow from financing activities for the current period is -CNY 128,660,899.54, compared to -CNY 361,063,945.95 in the previous period, showing an improvement[35]. - The total cash and cash equivalents at the end of the period is CNY 393,934,400.07, down from CNY 227,103,425.45 in the previous period[35]. - Cash and cash equivalents decreased to ¥393,934,400.07 from ¥1,089,345,444.58, a decline of approximately 63.8%[6]. Accounts Receivable and Inventory - Accounts receivable increased to ¥649,308,222.42 from ¥291,350,016.43, representing a growth of about 123.5%[6]. - Inventory increased to ¥788,287,399.63 from ¥749,171,033.03, an increase of approximately 5.2%[6]. - The company reported a significant increase in accounts receivable by 122.86%, reaching ¥64,930.82 million[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 53,717, with the top 10 shareholders holding a combined 56.05% of shares[21]. - Li Zhenguo holds 25.17% of shares, while Heilongjiang Cheneng Gongda Venture Capital Co., Ltd. holds 18.79%[21]. - The report indicates that there are no related party relationships among the top 10 shareholders, and they are not acting in concert[21]. Research and Development - The company’s subsidiary, Mudanjiang Youbo Pharmaceutical Co., Ltd., received approval for clinical trials of a new drug, YB211, from the National Medical Products Administration[24]. - Research and development expenses increased slightly to CNY 91,241,164.16 from CNY 88,935,071.45, reflecting a growth of about 2.5%[36]. Operating Costs - Total operating costs for the current period are CNY 2,066,143,905.54, down from CNY 2,217,629,799.25, representing a reduction of about 6.8%[36]. - The company reported a decrease in sales expenses to CNY 869,241,636.60 from CNY 888,599,556.72, a reduction of approximately 2.9%[36].